EXAMINING DAPAGLIFLOZIN'S IMPACT ON CARDIOVASCULAR HEALTH IN HFREF PATIENTS: DIABETES TYPE 2 CONSIDERATION
Main Article Content
Keywords
Dapagliflozin, Heart Failure, Cardiovascular Outcomes, Type 2 Diabetes, Efficacy.
Abstract
Background: The drug Dapagliflozin, an SGLT2 inhibitor, has shown cardiovascular benefits in the case of heart failure. Nonetheless, it is uncertain whether the medication can help patients with heart failure who also have reduced ejection fraction (HFrEF) and type 2 diabetes mellitus which calls for more investigations.
Objective: To determine the effect of dapagliflozin on cardiovascular outcomes in heart failure patients with reduced ejection fraction (HFrEF) emphasizing differences by presence or absence of type 2 diabetes mellitus.
Study design: A Cross-sectional study
Place and duration of study: The Study was done at the Department of Endocrinology, HMC Peshawar from January 2021 to March 2021 lasting three months.
Methods: In total, there were one hundred and sixty persons under observation including eighty individuals suffering from type 2 diabetes and eighty patients without any such diagnosis. From January to March 2021; a cross-sectional observational study was conducted at the Department of Endocrinology in HMC Peshawar. Patients with HFrEF were stratified based on diabetes type 2 status and treatment with dapagliflozin, with cardiovascular outcomes assessed and compared between groups.
Results: The study consisted of an equal number of subjects divided into two categories according to whether they had been diagnosed as having type-2 diabetes or not. Treatment by means of dapagliflozin proved successful to this end. In terms of frequency for hospitalization which plummeted down to (0.9 ± 0.2) in T2DM group compared to that in non-T2DM group (0.7 ±0.3). Additionally; EF increased significantly (+5%) whilst a prolonged walking time via six minutes’ walk test occurred (+40%) after using it as well.The adverse effects were low (10%in T2DM group, 12% in non-T2DM). Comparison with control groups revealed favored outcomes. In light of this the findings indicate ace efficacy of dapagliflozin irrespective of type 2 diabetes status in protecting cardiovascular health on heart failure patients underlining its potential clinical importance.
Conclusion: Dapagliflozin demonstrates efficacy in improving cardiovascular outcomes in heart failure patients, irrespective of type 2 diabetes status. These findings support its potential as a therapeutic option for heart failure with reduced ejection fraction, warranting further exploration in clinical practice and future research endeavors.
References
2. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008.
3. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424.
4. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357.
5. Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation. 2019;139(11):1384-1395.
6. Docherty KF, Jhund PS, Inzucchi SE, et al. Effects of dapagliflozin in DAPA-HF according to background diabetes therapy. Diabetes Obes Metab. 2021;23(5):1061-1067.
7. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008.
8. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128.
9. Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140(18):1463-1476.
10. Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73(15):1931-1944.
11. Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020;383(15):1425-1435.
12. Heerspink HJL, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752-772.
13. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845-854.
14. Januzzi JL Jr, Butler J, Jarolim P, et al. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol. 2017;70(6):704-712.
15. Docherty KF, Jhund PS, Inzucchi SE, et al. Dapagliflozin in heart failure patients with reduced ejection fraction: a population-based cohort study. Eur J Heart Fail. 2020;22(1):99-109.
16. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384(2):117-128.
17. Verma S, Mazer CD, Yan AT, et al. Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation. 2019;140(21):1693-1702.
18. Kato ET, Silverman MG, Mosenzon O, et al. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019;139(22):2528-2536.
19. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-39.
20. Docherty KF, Jhund PS, Inzucchi SE, et al. Effects of dapagliflozin in heart failure patients with reduced ejection fraction: a population-based cohort study. Eur J Heart Fail. 2020;22(1):99-109.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Khalid Usman
Associate professor, Department of Diabetes and Endocrinology, Hayatabad Medical Complex, Peshawar, Pakistan
Mujeeb ur Rehman
Assistant Professor, Department of Diabetes and Endocrinology, Lady Reading Hospital, Peshawar, Pakistan
Arif Mumtaz
Assistant Professor, Department of Medicine, KMU Institute Medical Sciences, Kohat, Pakistan
Naseeb UrRehman
Associate Professor of Medicine, Khlifa Gulnawaz Teaching Hospital, Bannu, Pakistan
Salman Khan
Associate Professor of Medicine, DHQ Teaching Hospital, Dera Ismail Khan, Pakistan